Evidence map›Paper›PMID 26820992›Full record

ArticleOncogene2016

Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.

M Tumiati, P M Munne, H Edgren, S Eldfors, A Hemmes, S G Kuznetsov

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

M TumiatiInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
P M MunneInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
H EdgrenInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
S EldforsInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
A HemmesInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
S G KuznetsovInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Institute for Molecular Medicine Finland · FIUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Almost half of all hereditary breast cancers (BCs) are associated with germ-line mutations in homologous recombination (HR) genes. However, the tumor phenotypes associated with different HR genes vary, making it difficult to define the role of HR in BC predisposition. To distinguish between HR-dependent and -independent features of BCs, we generated a mouse model in which an essential HR gene, Rad51c, is knocked-out specifically in epidermal tissues. Rad51c is one of the key mediators of HR and a well-known BC predisposition gene. Here, we demonstrate that deletion of Rad51c invariably requires inactivation of the Trp53 tumor suppressor (TP53 in humans) to produce mammary carcinomas in 63% of female mice. Nonetheless, loss of Rad51c shortens the latency of Trp53-deficient mouse tumors from 11 to 6 months. Remarkably, the histopathological features of Rad51c-deficient mammary carcinomas, such as expression of hormone receptors and luminal epithelial markers, faithfully recapitulate the histopathology of human RAD51C-mutated BCs. Similar to other BC models, Rad51c/p53 double-mutant mouse mammary tumors also reveal a propensity for genomic instability, but lack the focal amplification of the Met locus or distinct mutational signatures reported for other HR genes. Using the human mammary epithelial cell line MCF10A, we show that deletion of TP53 can rescue RAD51C-deficient cells from radiation-induced cellular senescence, whereas it exacerbates their centrosome amplification and nuclear abnormalities. Altogether, our data indicate that a trend for genomic instability and inactivation of Trp53 are common features of HR-mediated BCs, whereas histopathology and somatic mutation patterns are specific for different HR genes.

Indexed as

AnimalsBreast NeoplasmsDisease Models, AnimalDNA-Binding ProteinsFemaleGene DeletionGerm-Line MutationHomologous RecombinationHumansMammary Neoplasms, AnimalMiceMice, KnockoutRad51 RecombinaseTumor Suppressor Protein p53DNA-Binding ProteinsRAD51C protein, mouseRad51 RecombinaseTumor Suppressor Protein p53

Identifiers

PMID26820992
OpenAlexW2267803702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.